An analysis of data from seven clinical trials shows a drug designed to treat epileptic seizures in adults was equally effective with children, according to findings presented at the recent American Academy of Neurology meeting in Boston.
In a revised approach to its plan with Arena Pharmaceuticals Inc. dating to November 2013, Eisai Inc. recently agreed to purchase all development and marketing rights for Arena’s weight loss treatment medication, lorcaserin hydrochloride CIV.
Eisai Co. Ltd. recently made a public statement concerning its anticancer agent, Treakisym for Injection 100 mg, which has gained approval for an additional indication of chronic lymphocytic leukemia in Japan.
The U.S. Food and Drug Administration (FDA) recently stated that there was sufficient evidence of a novel investigational oral beta-secretase cleaving enzyme (BACE) inhibitor E2609 to begin phase III clinical studies.
Eisai Co. Ltd., based in Tokyo, recently withdrew the company’s new drug application for its ultra-high dose mecobalamin, which was designed to treat amyotrophic lateral sclerosis patients living in Japan.
Eisai Co. Ltd. recently stated that it has received approval from Japan to use its in-house-discovered antiepileptic drug Fycompa for an adjunctive therapy against partial-onset seizures or primary generalized tonic-clonic seizures.
Obesity is a global epidemic. Studies have shown that more than 1.4 billion adults across the globe are overweight, and that 500 million of those people are considered obese. For people who are ready to try a pharmaceutical weight loss route, a new therapy may soon be available.